{"id":16912,"date":"2022-04-25T12:11:41","date_gmt":"2022-04-25T16:11:41","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=16912"},"modified":"2022-05-03T13:46:02","modified_gmt":"2022-05-03T17:46:02","slug":"178882-awarded-in-funding-for-cystic-fibrosis-research","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/pt\/178882-awarded-in-funding-for-cystic-fibrosis-research\/","title":{"rendered":"EE anuncia $178,882 em financiamento para investiga\u00e7\u00e3o sobre fibrose c\u00edstica"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">Em fevereiro de 2022, anunci\u00e1mos que a Emily's Entourage (EE) tinha atribu\u00eddo <\/span><a href=\"https:\/\/www.emilysentourage.org\/pt\/440000-awarded-in-round-6-funding-for-cystic-fibrosis-research\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">$440,000 em financiamento<\/span><\/a><span style=\"font-weight: 400;\"> para duas novas bolsas destinadas a promover a investiga\u00e7\u00e3o e o desenvolvimento de medicamentos para a fibrose qu\u00edstica (FC). Hoje, estamos entusiasmados por partilhar que a EE atribuiu um montante adicional de $178.882 a um terceiro benefici\u00e1rio de uma subven\u00e7\u00e3o, a Mitochon Pharmaceuticals, Inc., para fazer avan\u00e7ar a investiga\u00e7\u00e3o sobre a disfun\u00e7\u00e3o mitocondrial nas pessoas com FC.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Mais informa\u00e7\u00f5es sobre esta subven\u00e7\u00e3o est\u00e3o dispon\u00edveis abaixo.<\/span><\/p>\n<h2><strong>BENEFICI\u00c1RIO DA SUBVEN\u00c7\u00c3O:<\/strong><\/h2>\n<hr \/>\n<h3 style=\"padding-left: 40px;\"><b>Utilidade terap\u00eautica do MP-101 para a fibrose qu\u00edstica<br \/>\n<\/b><\/h3>\n<p style=\"padding-left: 40px;\"><img decoding=\"async\" class=\"alignleft wp-image-16915 size-thumbnail\" src=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Dr.-Geisler-1-150x150.png\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Dr.-Geisler-1-150x150.png 150w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Dr.-Geisler-1.png 300w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Dr.-Geisler-1-12x12.png 12w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Dr.-Geisler-1-100x100.png 100w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/p>\n<p style=\"padding-left: 40px;\"><img decoding=\"async\" class=\"wp-image-16919 size-thumbnail alignleft\" src=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Robert-Alonso-150x150.png\" alt=\"\" width=\"150\" height=\"150\" srcset=\"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Robert-Alonso-150x150.png 150w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Robert-Alonso.png 300w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Robert-Alonso-12x12.png 12w, https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Headshot-Robert-Alonso-100x100.png 100w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">John G. Geisler, PhD, CSO e cofundador (\u00e0 esquerda)<\/span><br \/>\n<span style=\"font-weight: 400;\">Robert Alonso, MBA, Diretor Executivo e cofundador (\u00e0 direita)<\/span><\/p>\n<p style=\"padding-left: 40px;\"><i><span style=\"font-weight: 400;\">Mitochon Pharmaceuticals, Inc.<\/span><\/i><\/p>\n<p style=\"padding-left: 40px;\"><span style=\"font-weight: 400;\">A disfun\u00e7\u00e3o mitocondrial \u00e9 um problema frequentemente ignorado nas pessoas com FC. \u00c9 marcada por uma produ\u00e7\u00e3o de energia deficiente e pela gera\u00e7\u00e3o de enormes n\u00edveis de radicais livres que s\u00e3o t\u00f3xicos para todas as c\u00e9lulas do corpo. O trabalho da Mitochon representa uma nova abordagem para a FC, na medida em que utiliza um modulador mitocondrial, o MP-101, para reduzir a produ\u00e7\u00e3o de radicais livres e a sobrecarga de c\u00e1lcio mitocondrial, reduzindo assim as respostas inflamat\u00f3rias e os consequentes danos nos tecidos. O MP-101 ser\u00e1 testado num modelo de FC em fur\u00e3o e, se for bem sucedido, poder\u00e1 ser testado em doentes com FC. <\/span><\/p>\n<hr \/>\n<p><span style=\"font-weight: 400;\">Saiba mais sobre os outros dois benefici\u00e1rios de subs\u00eddios da sexta ronda, <\/span><a href=\"https:\/\/www.emilysentourage.org\/pt\/440000-awarded-in-round-6-funding-for-cystic-fibrosis-research\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">anunciado em fevereiro de 2022<\/span><\/a><span style=\"font-weight: 400;\">cujo trabalho se centra no desenvolvimento de um novo modelo de fur\u00e3o com muta\u00e7\u00e3o nonsense e de uma nova forma de terapia gen\u00e9tica utilizando nanopart\u00edculas lip\u00eddicas.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Estamos gratos a todos os cientistas dedicados que est\u00e3o a liderar o esfor\u00e7o para satisfazer rapidamente as necessidades cr\u00edticas n\u00e3o satisfeitas de todas as pessoas com FC - ningu\u00e9m fica para tr\u00e1s! Ver um <\/span><a href=\"https:\/\/www.emilysentourage.org\/pt\/awarded-grants\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">listagem exaustiva<\/span><\/a><span style=\"font-weight: 400;\"> de todas as bolsas de investiga\u00e7\u00e3o concedidas.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Em fevereiro de 2022, anunciamos que a Emily's Entourage (EE) concedeu $440.000 em financiamento para duas novas bolsas para promover a pesquisa e o desenvolvimento de medicamentos para a fibrose c\u00edstica (FC). Hoje, estamos entusiasmados em compartilhar que a EE concedeu um adicional de $178,882 a um terceiro benefici\u00e1rio de bolsa, Mitochon Pharmaceuticals, Inc., para avan\u00e7ar na pesquisa sobre disfun\u00e7\u00e3o mitocondrial naqueles ... <\/p>\n<div class=\"clear\"><\/div>\n<p><a href=\"https:\/\/www.emilysentourage.org\/pt\/178882-awarded-in-funding-for-cystic-fibrosis-research\/\" class=\"excerpt-read-more\">Ler mais<\/a><\/p>","protected":false},"author":1281,"featured_media":16960,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"EE Announces $178,882 in Funding for Cystic Fibrosis Research","_seopress_titles_desc":"We are thrilled to share that EE has awarded an additional $178,882 to a third grant recipient, Mitochon Pharmaceuticals, Inc., to advance research into mitochondrial dysfunction in those with CF.","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"none","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[{"_seopress_pro_rich_snippets_type":"none"}],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-16912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/mitochon.png","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/posts\/16912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/users\/1281"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/comments?post=16912"}],"version-history":[{"count":5,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/posts\/16912\/revisions"}],"predecessor-version":[{"id":16920,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/posts\/16912\/revisions\/16920"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/media\/16960"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/media?parent=16912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/categories?post=16912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/pt\/wp-json\/wp\/v2\/tags?post=16912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}